Background: Tumor-induced immunosuppression can impede tumor-specific immune responses and limit the effects of cancer immunotherapy. The aim of this study was to investigate the possible effects of sequential chemoimmunotherapeutic strategies to enhance antitumor immune responses. Methods: Using the E7-expressing tumor TC-1 as the tumor model, the treatment groups were divided into the following groups: (1) inactivated allogeneic leukocyte infusion (ALI), (2) ALI þ MMC-inactivated TC-1 cell vaccine, and (3) ALI þ MMC-inactivated TC-1 cell vaccine þ cyclophosphamide (CTX). Results: In our study, we demonstrated that treatment with immune-modulating doses of CTX results in a beneficial tumor microenvironment with the suppression of Tregs. ALI has a limited therapeutic effect, as does the MMC-inactivated TC-1 cell vaccine. Our results showed that CTX preconditioning and persistent ALI treatment along with the MMC-inactivated TC-1 cell vaccine resulted in significant inhibition of tumor growth and extended survival. Conclusion: Our study illustrated the effects of immune-modulating doses of a sequential chemoimmunotherapeutic strategy targeting the tumor and its microenvironment. The results suggest potential clinical effects for the immunotherapy of HPV-associated malignancies.
Introduction
Human papillomavirus (HPV) accounts for approximately 5.3% of cancers throughout the world and consists of cervical cancer and subsets of genital and head and neck cancer. 1, 2 It is estimated that 50 million women carry HPV, and approximately 500,000 women develop cancer yearly, 3 posing a threat to human health worldwide. Thus, there is a significant need to develop better strategies to treat HPV-induced lesions.
Tumor-induced immunosuppression plays a critical role in preventing tumor-specific immune responses and decreasing the effect of cancer immunotherapy. 4, 5 There is growing acknowledgment that there may be significant advantages to eliciting immune responses against a broad spectrum of antigens expressed by cancer cells rather than targeting a single antigen. 6, 7 Allogeneic transplantation (including hematopoietic stem cell transplantation) has been used as a successful therapeutic method for tumor treatment. 8 It is well recognized that Conflicts of interest: The authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article.alloantigens can induce powerful cellular and humoral immune responses and play an important role in graft vs. host (GVH) or host vs. graft (HVG) response. However, both GVH and HVG biology have many antitumor mechanisms in common, such as antigen presenting cell (APC) activation, 9 fasand perforin-based cytolysis 10 and IFN-g-secreting type 1 T cells. 11 Therefore, it is possible to use these characteristics as therapeutic methods.
Over the past 20 years, the efforts to create antitumor immune responses have been based on the sophisticated mechanisms of T cell activation and antigen presentation. However, in an allogeneic transplantation model, the phenomenon in which the powerful host T cell immune reaction to allogeneic major histocompatibility complex (MHC) molecules has drawn little attention. A recent study illustrated the application potential for the allogeneic response to induce weak selfrestricted T cell responses to tumor Ags. 12 This study raised the prospect of a novel allogeneic immunotherapy for patients with malignant tumors.
The tumor microenvironment plays an important role in impeding the clinical responses. 13 Novel strategies should be based on targeting the tumor and its microenvironment. It is widely believed that immune-modulating doses of chemotherapeutic drugs induce a powerful response of the immune cells in the tumor microenvironment and exert an antitumor reaction.
14e16 Therefore, the combination of effective chemotherapeutic agents with immunotherapy may elicit the optimal clinical response in cancer patients.
In the present study, to explore the antitumor effect, we combined cyclophosphamide (CTX), MHC-unmatched allogeneic leukocytes and inactivated TC-1 tumor cells in a mouse subcutaneous TC-1 tumor model. The purpose was to establish the theoretical and experimental basis for a novel sequential biological treatment for HPV-induced lesions. We hope that this will be a promising strategy for clinical study as a cure of HPV-related cancer in the near future.
Methods

Mice and cell lines
Inbred female C57BL/6 (B6, H-2) mice (8e10 weeks) were purchased from the Experimental Animal Institute of Peking Union Medical College. All animals were maintained under specific pathogen-free conditions, and all procedures were performed according to approved protocols and in accordance with recommendations for the proper care of laboratory animals.
TC-1 tumor cells derived from primary epithelial cells of C57BL/6 mice co-transformed with HPV-16 E6, E7 and c-Haras oncogenes were provided by Dr. T.C. Wu from Johns Hopkins University. The following standard experimental mouse tumor cell lines were used in vitro and in vivo: B16-F10 (H-2b) melanoma and YAC-1 lymphoma.
TC-1, B16-F10 and YAC-1 cells were cultured in RPMI 1640 (Gibco-BRL, Carlsbad, CA) supplemented with 10% fetal calf serum containing 10% fetal bovine serum (HyClone, Logan, UT) in the presence of 200 mg/mL of Geneticin (G418) at 37 C with 5% CO 2 .
Cell vaccine preparation
Murine splenocytes were separated from freshly spleens of BALB/c mice. For inactivating splenocytes, 25 mg/mL mitomycin C (MMC) were taken into the cell suspension in a concentration of 1 Â 10 7 cells/mL. Meanwhile, 100 mg/mL mitomycin C (MMC) were taken into the TC-1 cell suspension in a concentration of 1 Â 10 6 cells/mL. And the cells were incubated for 60 min. At last the cell were washed with phosphate-buffered saline (PBS) and resuspended.
Reagents
CTX (Cat. C0768; SigmaeAldrich, Milwaukee, WI) was dissolved at 10 mg/mL in deionized water.
Therapeutic tumor experiment protocol
On Day 0, mice were injected subcutaneously (s.c.) on the right flank with 1 Â 10 5 TC-1 tumor cells. On Day 10, mice bearing tumors approximately 60 mm 3 were arbitrarily assigned to six groups as follows: the PBS control group; TC-1 cell vaccine group; ALI groups (4 Â 10 7 , 2 Â 10 7 , 1 Â 10 7 ); CTX group; ALI and TC-1 cell vaccine group; and the CTX, ALI and TC-1 cell vaccine group. CTX was given intraperitoneally (i.p.) at a dose of 50 mg/kg on Day 10 after tumor challenge. On Day 11, the MMC-inactivated allogeneic leukocytes were administered intratumorally (i.t.) and repeated twice every 3 days. On Day 12, the 2 Â 10 6 MMC-inactivated cancer cells were injected subcutaneously (s.c.) and then boosted twice every 3 days. Tumors were monitored every 3 days, and the survival of mice was recorded. Tumor dimensions were measured with calipers, and the values were inserted into the following formula: tumor volume (mm
). The number of deaths was assessed at each interval. All measurements were obtained in a strictly blinded fashion.
Flow cytometry
TC-1 cancer cells were incubated for 30 min with an optimal concentration of FITC-conjugated anti-mouse MHC Class I (Cat. 11-5999; eBioscience, San Diego, CA) on ice and then washed twice with cold phosphate buffered saline (PBS).
For the samples obtained from fresh TC-1 carcinoma masses, separation of the tumor-infiltrating mononuclear cells was carried out by differential gradient centrifugation, and the tumor-infiltrating mononuclear cells were found at the interface of 75% and 100% Ficoll-Hypaque. For samples obtained from spleens, erythrocytes were removed by suspending the cells in lysis buffer and then rinsing the cells twice with RPMI 1640. Cells were incubated for 30 min with an optimal concentration of antibodies on ice and then washed twice with cold phosphate buffered saline (PBS). The following antibodies were used in the experiments: Alexa FluorVR 488 anti -mouse/rat/human FOXP3 antibody (Cat. 320011; Biolegend, San Diego, CA), PE/Cy5 anti-mouse CD4 antibody (Cat. 100409; Biolegend), PE-conjugated anti-mouse CD25 (Cat. 102007; Biolegend). Analysis was performed on a FACScan (EPICS ELITE ESP model; Beckman Coulter, Fullerton, CA), and data were analyzed with the Expo32 software (Beckman Coulter).
Cytotoxicity assays
TC-1-bearing mice were treated according to the treatment protocol described earlier. Three days after the third administration of the combined cell vaccine, splenocytes from treated mice were prepared as effector cells. Cytotoxicity assays were performed using a CytoTox 96 ® Nonradioactive Cytotoxicity Assay kit (Promega, Madison, WI) according to the manufacturer's instructions. B16-F10, TC-1 and YAC-1 cells were used as target cells. Effector cells were added to target cells at a ratio of 60:1, 30:1 and 15:1 (tested in triplicate).
Statistical analysis
For comparison, ANOVA was used for the comparisons among 3 or more groups of individual time points. Student's t-test was used to compare means between the 2 groups. Logrank test were analyzed in the survival data. Differences were considered to be significant when p < 0.05. Statistical analysis was performed using commercially available software (SPSS 11.0).
Results
Subcutaneous injection of the MMC-inactivated TC-1 cell vaccine has a limited therapeutic effect
To investigate the antitumor immunity, we challenged mice with 1 Â 10 5 TC-1 tumor cells/mouse, then immunized mice with MMC-inactivated TC-1 tumor cells. As shown in Fig. 1 , compared with the PBS control group, the therapy group showed no significant difference ( p > 0.05). This result demonstrated that subcutaneous injection of MMC-inactivated TC-1 tumor cells as a vaccine has limited effects.
Allogeneic leukocyte infusion (ALI) has a limited therapeutic effect
We used the TC-1 tumor model to examine the antitumor effects of allogeneic leukocyte infusion (ALI). As shown in Fig. 2A, TC-1 . The 4 Â 10 7 group appeared to have some effect, but its effect was not significantly different from that of the PBS group ( p > 0.05). Fig. 2B shows that compared with PBS, ALI was unable to increase the lifespan of tumorbearing mice ( p > 0.05).
Sequential immune-modulating doses of CTX and combined vaccine treatment dramatically improved the antitumor effect
We then hypothesized that the sequential strategy of CTX, ALI and TC-1 cell vaccine would overcome immune evasion and induce a powerful antitumor immune response. The tritherapy has a greater effect on inhibiting tumor growth than the single treatments or bitherapy strategy. On Day 24, tumor growth was inhibited 56% in the CTX þ ALI þ TC-1 cell vaccine group (804.36 ± 229.24 mm
3 ) compared with that in the control group (1835.01 ± 533.96 mm 3 , p < 0.05; Fig. 3B ). No significant inhibition was observed in the ALI þ TC-1 cell vaccine group or the CTX-treated group. Compared with the administration of PBS, the administration of CTX, ALI and TC-1 cell vaccine also increased the lifespan of tumor-bearing mice ( p < 0.05). The mean survival time (MST) of the PBS group was 45.6 days, whereas the CTX þ ALI þ TC-1 cell vaccine group was 54.4 days ( Table 1) . Compared with the PBS control group, the ALI and TC-1 cell vaccine group could also increase the MST by 5.2 days (50.8 vs. 45.6, Table 1 ), which demonstrated that the administration of the ALI and TC-1 cell vaccine may have some therapeutic effect.
TC-1 cancer cells express normal levels of major histocompatibility complex (MHC) class I molecule
One example of tumor evasion mechanisms is the loss of MHC-I expression. We determined the level of MHC-I expression using FACS. Fig. 4 illustrates that TC-1 cancer cells express normal levels of major histocompatibility vaccine suppressed Treg populations. The proportion of CD4 þ CD25 þ FoxP3 þ /CD4þ lymphocytes in the combined treatment were 7.7 ± 3.1% in spleens and 11.9 ± 1.5% in tumors compared with 17.1 ± 1.8% and 33.2 ± 5.7% in the PBS group ( p < 0.05), respectively. Compared with PBS, CTX primarily decreased Tregs in spleens ( p < 0.05) and tumors ( p < 0.05).
Tritherapy in established tumors induces innate and adaptive antitumor response
In the current study, we asked whether antitumor cytotoxicity was detectable after tritherapy in established tumors. Splenocytes from animals in which TC-1 tumors were inhibited by tritherapy demonstrated cytolysis activity toward TC-1 tumor cells in vitro rather than B16-F10 (Fig. 5) , whereas splenocytes from PBS treated mice failed to demonstrate lysis toward either TC-1 or B16-F10. Thus, it appears that a measurable CTL response was activated in a tumor-bearing mouse only when the tumor was inhibited by tritherapy treatment. Further, tritherapy treatment also resulted in significant cytotoxicity against NK-sensitive YAC-1 cells (see Fig. 6 ).
Discussion
Tumor microenvironments consist of proliferating cancer cells, infiltrating inflammatory cells, tissue cells, and blood vessels. The tumor modifies the function of infiltrating cells to create a microenvironment favorable for tumor progression 17 Recent research suggests that oncologic therapies, such as chemotherapy, surgery, and radiation, can induce Tregs and strengthen their suppressing functions.
18e20 Tregs in the host immune system produce an imbalance that could not be corrected by immunotherapies targeting only activation of antitumor responses. 21 Another study illustrated a large number of tumor-infiltrating and splenic Tregs activated during the growth of TC-1 tumors. 22, 23 Cyclophosphamide (CTX) is a non-specific cytotoxic drug, which exerts its biological effects by interfering with cellular DNA synthesis. CTX could decrease the number of Tregs and suppress the remaining Tregs. 24 The studies reported that CTX enhanced the effect of tumor vaccines and adoptive transfer of antigen-specific lymphocytes. CTX is known as an immunosuppressive agent and studies have shown that patients who were given CTX had depleted Treg cells, which were involved in cancer-induced immune tolerance. 25 Moreover, CTX administration downregulated the expression of glucocorticoid-induced TNF receptor (GITR) and Foxp3. 24e27 Another study illustrated that the timing between CTX administration and vaccine injection is essential to induce the antitumor response. 28 CTX administration regulated the immune system in the priming vaccination phase. Immune-modulating doses of CTX could elicit the selective effect against Tregs, and we did not find the autoimmune signs such as decrease in weight, lymphopenia and other toxicities in each group (data not shown).
In the present study, we reported the antitumor potential of MHC-unmatched allogeneic leukocytes which had been mitotically inactivated to prevent GVHD. This situation mimics one-way allogeneic mixed leukocyte reaction (MLR) in vivo. Other researchers have illustrated that both one-way and two-way MLR elicit an intense release of cytokines, especially type 1 cytokines (e.g. TNF-a and IFN-g). 29, 30 Therefore, we assumed that an in vivo MLR may lead to a proinflammatory, adjuvant effect of the host immune cells and break the autologous immune tolerance of tumor cells. The ability of graft rejection to elicit antitumor reaction was illustrated in a clinical test of skin transplantation from HLAunmatched donors. 31 Measurable disease responses were reported in patients with hormone-refractory prostate cancer. This study illustrated antitumor effects induced by HLAunmatched donor skin transplantation.
In the tritherapy strategy, we first used CTX to decrease the Tregs in the tumor microenvironment, followed by ALI to break the immune tolerance, and finally, we injected inactivated TC-1 tumor cells subcutaneously to provide the tumorspecific antigen. The efficient cross-presentation of tumorspecific antigen (TSA) is pivotal for the effects of cancer immunotherapy. Cross-presentation comprises antigen internalization, processing, and the presentation of peptides on MHC-I molecules by DCs. 32 As the TC-1 tumor can express high levels of MHC-I molecules (Fig. 4) , the crosspresentation would be effective.
Combining chemotherapy to immunotherapy has been demonstrated effective in some preclinical trials and in a clinical model. In this study, we demonstrated a novel potent tritherapy of CTX, ALI and a cancer cell vaccine and showed that it was effective for the treatment of TC-1 tumors when administered in a sequential regimen. The addition of CTX is feasible and well tolerated, and it is familiar to clinicians. 33 In conclusion, the sequential combined chemotherapy to immunotherapy scheme induces a beneficial host microenvironment. It will be essential to test this combination scheme on tumors that express associated tumor antigens. Reversal of tumor-mediated immunosuppression will be necessary for the success of immunotherapies. These findings are very encouraging for subsequent clinical development in the field of HPV therapeutic vaccines.
